These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 161840)

  • 1. [Molybdocene dichloride as an antitumor agent (author's transl)].
    Köpf-Maier P; Leitner M; Voigtländer R; Köpf H
    Z Naturforsch C Biosci; 1979 Dec; 34(12):1174-6. PubMed ID: 161840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].
    Köpf-Maier P; Hesse B; Köpf H
    J Cancer Res Clin Oncol; 1980 Jan; 96(1):43-51. PubMed ID: 7188941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cell growth inhibition by metallocene dichlorides.
    Köpf-Maier P; Wagner W; Köpf H
    Cancer Chemother Pharmacol; 1981; 5(4):237-41. PubMed ID: 7261252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organometallic anticancer agents: cellular uptake and cytotoxicity studies on thiol derivatives of the antitumor agent molybdocene dichloride.
    Waern JB; Dillon CT; Harding MM
    J Med Chem; 2005 Mar; 48(6):2093-9. PubMed ID: 15771451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis-diamminedichloroplatinum(II) and metallocene dichlorides.
    Köpf-Maier P; Wagner W; Liss E
    J Cancer Res Clin Oncol; 1981; 102(1):21-30. PubMed ID: 7199526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
    Köpf-Maier P; Hesse A
    J Cancer Res Clin Oncol; 1984; 108(2):254-5. PubMed ID: 6540782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Titanocene dichloride--the first metallocene with cancerostatic activity.
    Köpf H; Köpf-Maier P
    Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor properties of organometallic metallocene complexes of tin and germanium.
    Köpf-Maier P; Janiak C; Schumann H
    J Cancer Res Clin Oncol; 1988; 114(5):502-6. PubMed ID: 3182909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of various antitumor agents on intracerebrally inoculated Ehrlich ascites carcinoma in mice (author's transl)].
    Zhou JX; He GH; Tao LX; Xu B
    Zhongguo Yao Li Xue Bao; 1981 Dec; 2(4):256-61. PubMed ID: 6462026
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect.
    Köpf-Maier P; Wagner W; Hesse B; Köpf H
    Eur J Cancer (1965); 1981 Jun; 17(6):665-9. PubMed ID: 7308264
    [No Abstract]   [Full Text] [Related]  

  • 11. The first organoantimony(III) compounds possessing antitumor properties: diphenylantimony(III) derivatives of dithiophosphorus ligands.
    Silvestru C; Socaciu C; Bara A; Haiduc I
    Anticancer Res; 1990; 10(3):803-4. PubMed ID: 2369094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states.
    Köpf-Maier P; Klapötke T
    J Cancer Res Clin Oncol; 1992; 118(3):216-21. PubMed ID: 1548287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spermicidal activity of metallocene complexes containing vanadium(IV) in humans.
    D'Cruz OJ; Ghosh P; Uckun FM
    Biol Reprod; 1998 Jun; 58(6):1515-26. PubMed ID: 9623614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro.
    Köpf-Maier P; Wagner W; Liss E
    J Cancer Res Clin Oncol; 1983; 106(1):44-52. PubMed ID: 6684118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
    Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
    Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor organometallics. I. Activity of some diphenyltin(IV) and diphenylantimony(III) derivatives on in vitro and in vivo Ehrlich ascites tumor.
    Bara A; Socaciu C; Silvestru C; Haiduc I
    Anticancer Res; 1991; 11(4):1651-5. PubMed ID: 1836124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor metallocenes: new developments and toxicologic features.
    Köpf-Maier P; Köpf H
    Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionic rhenocene derivatives with antitumor activity.
    Köpf-Maier P; Klapötke T
    Cancer Chemother Pharmacol; 1992; 29(5):361-6. PubMed ID: 1551174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor inhibition by titanocene dichloride: first clues to the mechanism of action.
    Köpf-Maier P; Köpf H
    Naturwissenschaften; 1980 Aug; 67(8):415-6. PubMed ID: 7191057
    [No Abstract]   [Full Text] [Related]  

  • 20. Coordination chemistry of the antitumor metallocene molybdocene dichloride with biological ligands.
    Waern JB; Harding MM
    Inorg Chem; 2004 Jan; 43(1):206-13. PubMed ID: 14704069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.